Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Chemistry

Abstract 2655: Apoptotic peptide hybrid for treatment of chemotherapy-resistant cancers

Ji-seon Kim
Ji-seon Kim
1University of Tennessee Health Science Center, Memphis, TN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-2655 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Resistance to chemotherapy is one of the major obstacles to successful cancer treatment. Many cancer patients develop metastatic cancers after responding to initial treatment, which are often refractory to chemotherapy, and remain incurable. Inhibition of apoptotic pathways due to up-regulation of anti-apoptotic elements, such as Bcl-2 and IAPs (inhibitors of apoptosis proteins) has been reported to account for the resistance to chemotherapeutic agents. Thus, it is critical to restore the inhibited apoptosis to re-sensitize the cancer to chemotherapy. In this study, we investigated whether a pro-apoptotic peptide and a proteasome inhibitor peptide can synergize to induce apoptosis in doxorubicin-resistant cancer cells in vitro. The pro-apoptotic peptide is a cationic amphipathic peptide which depolarizes mitochondrial membranes to release apoptosis initiators such as, cytochrom c and Smac/DIABLO to cell cytosols, which activate caspases, apoptosis executors by inhibiting IAPs (inhibitors of apoptosis proteins). MG132 (Z-Leu-Leu-Leu-CHO) has been reported to inhibit anti-apoptotic proteins including NF-[[Unable to Display Character: ĸ]]B and Bcl-2 family proteins to stimulate apoptosis. We hypothesized that when concurrently delivered to the same cells, KLA and MG132 would synergize to induce apoptosis in resistant cancer cells by acting on different stages of apoptotic pathways. To test this, we conjugated KLA and MG132 by forming acid-labile Schiff bases between ε-amino groups of lysines in KLA and the aldehyde group of MG132. We expected that the formed KLA-MG132 conjugates would be internalized into cells by pinocytosis then, dissociated in the acidic environment (pH 4 – 5) of lysosomes to release intact KLA and MG132. The conjugation efficiency was found to be ∼ 100%, as measured indirectly by quantifying amine groups of un-conjugated lysine residues by TNBS assay. The conjugation was confirmed further by determining the molecular masses of the formed conjugates by mass spectrometry after reducing the conjugates by NaBH4 to stabilize Schiff bases. The conjugates induced upto 50 % of cell death in doxorubicin-resistant human cancer cells at the concentration of 0.6 μM as determined by MTT assay meanwhile; un-conjugated MG132 and KLA were inactive at the same concentration. And, the levels of cytosolic cytochrome c were 2-fold greater in the cells treated with KLA-MG132 conjugates than in cells treated with MG132 alone. The levels of active caspase-3 were higher by up to 70 % in cells treated with KLA-MG132 conjugate than in cells treated with MG132 alone. In conclusion, we have observed that KLA and MG132 conjugated via Schiff base induced potent apoptosis in doxorubicin-resistant human cancer cell lines at sub-micromolar concentrations.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2655.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 2655: Apoptotic peptide hybrid for treatment of chemotherapy-resistant cancers
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 2655: Apoptotic peptide hybrid for treatment of chemotherapy-resistant cancers
Ji-seon Kim
Cancer Res April 15 2010 (70) (8 Supplement) 2655; DOI: 10.1158/1538-7445.AM10-2655

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 2655: Apoptotic peptide hybrid for treatment of chemotherapy-resistant cancers
Ji-seon Kim
Cancer Res April 15 2010 (70) (8 Supplement) 2655; DOI: 10.1158/1538-7445.AM10-2655
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract SY01-04: High-end proteomics enables identification of breast cancer therapy resistance predictive proteins
  • Abstract SY18-02: Targeting transcriptional regulators for simultaneous modulation of p53 and NF-κB in cancer treatment
  • Abstract SY11-03: Turning enzymes on with small molecules
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Drug Delivery and Disposition

  • Abstract 2658: Anti-GD3 antibodies are targeting molecules for delivery of RNAi to melanoma
  • Abstract 2644: Advanced nanoparticles with anticancer and MRI function for liver cancer in rats and rabbits
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement